Demecarium Bromide

Demecarium Bromide (CAS No.: 56-94-0) is a synthetic small molecule cholinesterase inhibitor used as a pharmacological research tool in ocular and neuropharmacology oriented discovery programs, primarily classified within enzyme modulator libraries for studies of cholinergic regulation. Available evidence indicates that it inhibits cholinesterase activity with high potency in the low micromolar to submicromolar range and has also been reported to modulate monoamine oxidase related enzymatic activity, supporting its use in mechanistic interrogation of neurotransmitter metabolism and autonomic signaling networks. Functionally, the compound is applied to investigate sustained enhancement of cholinergic tone through reduced acetylcholine hydrolysis, with downstream relevance to muscarinic signaling, pupillary constriction physiology, and pressure regulation phenotypes in ocular systems under experimental conditions. In vitro, it is commonly employed in enzyme and cell based assays to profile cholinesterase dependent responses, benchmark inhibitor sensitivity, and support structure activity or pathway level hypothesis testing, while in vivo preclinical work has included animal models assessing ocular pressure dynamics and pharmacodynamic persistence. In biomedical research and early drug discovery settings, Demecarium Bromide is therefore most appropriate as a reference inhibitor for target validation, pathway perturbation, and screening cascade calibration, and the concentrations or doses used in experiments typically depend on specific experimental designs, assay formats, and research objectives.